Company intelligence / Profile preview

OmniSeq

Buffalo, New York, United Statesoncology.labcorp.com ↗

Ownership: Private
Development stage: Commercial

Overview

OmniSeq developed advanced NGS-based molecular diagnostics to provide comprehensive tumor genomic and immune profiling. Its flagship product—OmniSeq INSIGHT—delivers actionable reports guiding oncologists toward the most effective targeted therapies or immunotherapies based on each patient’s tumor profile. The company’s tests have been used to match patients with FDA-approved treatments or clinical trials. In one case example cited in the media, their testing enabled successful use of pembrolizumab in an otherwise treatment-resistant cancer patient.

Therapeutic areas: Oncology
Modalities: Diagnostic test (NGS-based molecular profiling)
Industry: Molecular Diagnostics

Partnerships

Roswell Park Comprehensive Cancer Center was both an originator/founder and investor/partner prior to acquisition by Labcorp.

Beyond the preview

Go deeper on OmniSeq.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OmniSeq.

Explore the full profile